Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bristol-Myers Squibb ( (BMY) ) just unveiled an announcement.
Bristol Myers Squibb reported robust third-quarter results for 2024, with revenues rising to $11.9 billion, marking an 8% increase (10% when adjusted for foreign exchange). The company’s Growth Portfolio and U.S. approval of Cobenfy for schizophrenia played significant roles in this performance. Despite some challenges like generic erosion of Sprycel, the firm saw strong cash flow and increased revenue guidance. Investors should note the balance of GAAP and non-GAAP figures, reflecting strategic financial moves and a focus on sustainable growth.
For detailed information about BMY stock, go to TipRanks’ Stock Analysis page.